Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Oil Fund (DBO) vs Revvity Inc (RVTY) Price & Performance

Invesco DB Oil FundTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Oil Fund vs Revvity Inc — how do they compare? Invesco DB Oil Fund trades at $20.95, while Revvity Inc trades at $116.01 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while Invesco DB Oil Fund pays none, and Revvity Inc is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.

DBORVTY
Sector
Commodities - EnergyTechnology
52-Week High
$23.80$117.75
52-Week Low
$11.98$82.26
Market Cap
$12.91B
Enterprise Value
$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Oil Fund

DBO trades at $20.88, up 0.14% today, with a bullish technical signal driven by moving averages and neutral oscillators. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. The stock lacks disclosed financial ratios, limiting fundamental clarity amid sector-wide data reliability concerns.

Outlook hinges on oil price stability and company-specific updates, with upside potential from supply shocks but risks from demand weakness and geopolitical uncertainty. Investors await earnings and guidance for valuation anchors.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

About Invesco DB Oil Fund

DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.

Read more on DBO

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY